About Ro5
Ro5 is a Healthcare company based in London (United Kingdom) founded in 2018 by Will Montgomery, Roy Tal, and Zygimantas Jocys, and was acquired by Juvenescence in April 2025. AI-based drug discovery management tool is provided for researchers. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery.
Company details
Ro5 was founded in 2018 in London, United Kingdom, and operates in the biotechnology sector. An AI-driven platform is offered to support drug development strategies through database management. Features include tools for pharmacological studies, bioactivity analysis, and clinical trial evaluation. Assistance is provided to researchers in streamlining workflows and data handling within the pharmaceutical research domain.
- Headquarters London, United Kingdom
- Founders Will Montgomery, Roy Tal, Zygimantas Jocys
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website ro5.ai
- Social LinkedIn
- Acquired by Juvenescence (Apr 2025)
- Investors
- Acquired byJuvenescence
(Apr 2025)
Investors in Ro5
Ro5 has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Juvenescence.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health | 2017 | juvlabs.com | Dublin, Ireland |
Investor details for Ro5
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ro5
14 people are tracked at Ro5 (4 in leadership, 8 in board & advisors, 2 in team).
| Name | Role | Group |
|---|---|---|
Will Montgomery | Co-Founder | Leadership |
Roy Tal | Co-Founder | Leadership |
Zygimantas Jocys | Co-Founder | Leadership |
Charles Dazler Knuff | Founding CEO | Leadership |
John Howe | Advisor | Board & advisors |
Jeffrey Kindler | Advisor | Board & advisors |
Carol Routledge | Advisor | Board & advisors |
Robert Collins | Advisor | Board & advisors |
Tuvia Barak | Advisor | Board & advisors |
Timothy Tully | Advisor | Board & advisors |
Steven M. Katzman | Advisor | Board & advisors |
William C. Collins | Advisor | Board & advisors |
Tanya Paquet | Ro5 Leadership Team | Team |
Artem K. | Principal Data Scientist | Team |
Complete people profiles for Ro5
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Ro5
2 dated milestones of Ro5 across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Ro5 is founded.
- Exit Acquired by Juvenescence.
Top companies in Genomics & Gene Therapy Platforms
2 companies that operate in the same segment as Ro5 (Genomics & Gene Therapy Platforms) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Ro5
Ro5 was founded in 2018.
Ro5 is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Ro5 was founded in 2018 in London, United Kingdom, and operates in the biotechnology sector. An AI-driven platform is offered to support drug development strategies through database management. Features include tools for pharmacological studies, bioactivity analysis, and clinical trial evaluation. Assistance is provided to researchers in streamlining workflows and data handling within the pharmaceutical research domain.
Ro5 has 1 investor. Key investors include Juvenescence.
Yes. Ro5 was acquired by Juvenescence in April 2025.